Country
Full text data for US,EP,CN
Type
Legal Validity
Legal Status
Filing Date
Publication Date
Inventor
Assignee
Click to expand
IPC(Section)
IPC(Class)
IPC(Subclass)
IPC(Group)
IPC(Subgroup)
Agent
Agency
Claims Number
Figures Number
Citation Number of Times
Assignee Number
No. Publication Number Title Publication/Patent Number Publication/Patent Number Publication Date Publication Date
Application Number Application Number Filing Date Filing Date
Inventor Inventor Assignee Assignee IPC IPC
1 US2006292096A1
Cosmetic compositions having enhanced wear properties
Publication/Patent Number: US2006292096A1 Publication Date: 2006-12-28 Application Number: 11/168,796 Filing Date: 2005-06-28 Inventor: Yu, Wei   Assignee: L'OREAL   IPC: A61K8/89 Abstract: A cosmetic composition and process which provides enhanced wear and transfer resistance containing: (a) at least one polypropylsilsesquioxane film forming resin; (b) at least one solvent; and (c) optionally, at least one colorant.
2 US2006292101A1
In-eye method of cleaning and/or disinfecting silicone hydrogel contact lenses
Publication/Patent Number: US2006292101A1 Publication Date: 2006-12-28 Application Number: 11/475,278 Filing Date: 2006-06-27 Inventor: Borazjani, Roya   Salamone, Joseph   Barniak, Vicki   Scheuer, Catherine   Assignee: Borazjani, Roya   Salamone, Joseph   Barniak, Vicki   Scheuer, Catherine   IPC: A61K8/73 Abstract: A method of treating a contact lens, and in some instances, a silicone hydrogel contact lens, in the eye of a wearer comprising i) applying to said contact lens and/or eye an ophthalmically compatible contact lens cleaning and/or hydrating and/or disinfecting solution; and ii) rubbing the eyelid associated with said eye over the contact lens for at least about one second. A method of treating a contact lens, and in some instances, a silicone hydrogel contact lens, in the eye of a wearer comprising i) applying to said contact lens and/or eye an ophthalmically compatible contact lens cleaning and/or hydrating and/or disinfecting solution; and ii) ...More ...Less
3 US2006292102A1
Thixotropic personal lubricant
Publication/Patent Number: US2006292102A1 Publication Date: 2006-12-28 Application Number: 11/501,609 Filing Date: 2006-08-09 Inventor: Roman, Stephen   Kehoe, Gary   Assignee: Roman, Stephen   Kehoe, Gary   IPC: A61K8/73 Abstract: A thixotropic personal lubricant includes a high molecular weight, thixotropic, gel-forming, naturally occurring polysaccharide extracted from algae and comprised of repeating sulfated and non-sulfated galactose and 3,6 anhydrogalactose (3,6-AG) units, and includes water.
4 US2006292110A1
Coffee aroma vehicle air freshener
Publication/Patent Number: US2006292110A1 Publication Date: 2006-12-28 Application Number: 11/474,767 Filing Date: 2006-06-26 Inventor: Reinhardt, Ramona   Assignee: Reinhardt, Ramona   IPC: A61L9/00 Abstract: A car freshener comprising of a pre-formed material constructed to absorb a scent and a coffee flavored scent affixed to the pre-formed material.
5 US2006292133A1
Use of lactobacillus salivarius
Publication/Patent Number: US2006292133A1 Publication Date: 2006-12-28 Application Number: 11/311,632 Filing Date: 2005-12-20 Inventor: Collins, John   O'sullivan, Gerald   O'mahony, Liam   Shanahan, Fergus   Assignee: University College Cork - National University of Ireland, Cork   IPC: C12P1/04 Abstract: Lactobacillus salivarius is useful in the prophylaxis or treatment of undesirable inflammatory activity, especially gastrointestinal inflammatory activity such as inflammatory bowel disease or irritable bowel syndrome. The inflammatory activity may also be due to cancer. The Lactobacillus salivarius is of human origin isolated from resected and washed human gastrointestinal tract. One such strain is UCC 118 described in WO-A-9835014. Lactobacillus salivarius is useful in the prophylaxis or treatment of undesirable inflammatory activity, especially gastrointestinal inflammatory activity such as inflammatory bowel disease or irritable bowel syndrome. The inflammatory activity may also be due to cancer. The ...More ...Less
6 US2006292135A1
Use of bacterial phage-associated lysing proteins for preventing and treating bacterial infections in humans, animals and fowl
Publication/Patent Number: US2006292135A1 Publication Date: 2006-12-28 Application Number: 11/186,018 Filing Date: 2005-07-18 Inventor: Loomis, Lawrence   Fischetti, Vincent   Assignee: Loomis, Lawrence   Fischetti, Vincent   IPC: A61K38/43 Abstract: A composition and method for treating bacterial infections by the use of an effective amount of at least one lytic specific for the bacteria causing specific. The lytic enzyme is genetically coded for by a bacteriophage which may be specific for said bacteria. The enzyme may be at least one lytic protein or peptides in a natural or modified form. A composition and method for treating bacterial infections by the use of an effective amount of at least one lytic specific for the bacteria causing specific. The lytic enzyme is genetically coded for by a bacteriophage which may be specific for said bacteria. The enzyme may be ...More ...Less
7 US2006292136A1
Cytotoxic factors for modulating cell death
Publication/Patent Number: US2006292136A1 Publication Date: 2006-12-28 Application Number: 11/508,173 Filing Date: 2006-08-23 Inventor: Chakrabarty, Ananda   Das, Gupta Tapas   Punj, Vasu   Zaborina, Olga   Hiraoka, Yoshinori   Yamada, Tohru   Assignee: Chakrabarty, Ananda   Das Gupta, Tapas   Punj, Vasu   Zaborina, Olga   Hiraoka, Yoshinori   Yamada, Tohru   IPC: A61K38/44 Abstract: Cytotoxic factors having use in modulating cell death, and their use in methods of treating necrosis or apoptosis-related conditions are disclosed. The invention also relates to methods for identifying active agents useful in treating conditions related to cell death or uncontrolled growth. The present inventors have found that different microorganisms produce different cytotoxic factor(s) having anticancer activity. The substantially pure cytotoxic factors can be used in a method of treating an infectious disease or a cancer. Cytotoxic factors having use in modulating cell death, and their use in methods of treating necrosis or apoptosis-related conditions are disclosed. The invention also relates to methods for identifying active agents useful in treating conditions related to cell death or ...More ...Less
8 US2006292140A1
Humanized immunoglobulin reactive with alpha4beta7 integrin
Publication/Patent Number: US2006292140A1 Publication Date: 2006-12-28 Application Number: 11/511,164 Filing Date: 2006-08-28 Inventor: Ponath, Paul   Ringler, Douglas   Jones, S.   Newman, Walter   Saldanha, Jose   Bendig, Mary   Assignee: Ponath, Paul   Ringler, Douglas   Jones, S.   Newman, Walter   Saldanha, Jose   Bendig, Mary   IPC: A61K39/395 Abstract: The present invention relates to humanized immunoglobulins having binding specificity for α4β7 integrin, comprising an antigen binding region of nonhuman origin (e.g., rodent) and at least a portion of an immunoglobulin of human origin (e.g., a human framework region, a human constant region). In one embodiment, the humanized immunoglobulin can compete with murine Act-1 for binding to human α4β7 integrin. In a preferred embodiment, the antigen binding region of the humanized immunoglobulin comprises each of the complementarity determining regions of the light and heavy chains of the murine Act-1 antibody. The present invention relates to humanized immunoglobulins having binding specificity for α4β7 integrin, comprising an antigen binding region of nonhuman origin (e.g., rodent) and at least a portion of an immunoglobulin of human origin (e.g., a human framework ...More ...Less
9 US2006292143A1
Novel T-cell membrane protein (TIRC7), peptides and antibodies derived therefrom and uses thereof
Publication/Patent Number: US2006292143A1 Publication Date: 2006-12-28 Application Number: 11/510,868 Filing Date: 2006-08-25 Inventor: Utku, Nalan   Gullans, Steven   Milford, Edgar   Assignee: Utku, Nalan   Gullans, Steven   Milford, Edgar   IPC: A61K39/395 Abstract: Described are generally a T cell immune response cDNA 7 (TIRC7) encoding a novel T-cell transmembrane protein as well as peptides und polypeptides derived therefrom and antibodies recognizing said (poly)peptides. More particularly, peptide and polypeptide as well as antibodies being capable of inhibiting T-cell stimulation through the T-cell membrane protein (TIRC7) are provided. Furthermore, vectors comprising the aforementioned polynucleotides and host cells transformed therewith as well as their use in the production of the above-defined proteins, peptides or polypeptides are described. Additionally, pharmaceutical and diagnostic compositions are provided comprising any one of the afore described polynucleotide, vector, protein, peptide, polypeptide, or antibody. Furthermore, methods and uses for modulating immune responses through the novel TIRC7 membrane protein as well as pharmaceutical compositions comprising agents which act on the TIRC7 membrane protein or its ligand are described. Also, the use of said polynucleotide, vector, protein, peptide, polypeptide, or antibody for the preparation of pharmaceutical compositions for use in organ transplantation, for the treatment of autoimmune, allergic or infectious diseases, or for treatment of tumors is provided. Furthermore, methods for modulating (antigen-specific) T cell unresponsiveness inducing maintaining or reversing T cell unresponsiveness by inhibiting or stimulating an (unresponsive) T cell through the novel TIRC7 membrane protein are encompassed herein. Described are generally a T cell immune response cDNA 7 (TIRC7) encoding a novel T-cell transmembrane protein as well as peptides und polypeptides derived therefrom and antibodies recognizing said (poly)peptides. More particularly, peptide and polypeptide as well as antibodies ...More ...Less
10 US2006292147A1
Blood MMP-3 level-lowering agent comprising IL-6 antagonist as active ingredient
Publication/Patent Number: US2006292147A1 Publication Date: 2006-12-28 Application Number: 11/514,217 Filing Date: 2006-09-01 Inventor: Yoshizaki, Kazuyuki   Nishimoto, Norihiro   Okada, Yasunori   Obata, Ken-ichi   Assignee: Chugai Seiyaku Kabushiki Kaisha   IPC: A61K39/395 Abstract: A blood matrix metalloprotease-3 (MMP-3) level-lowering agent comprising an interleukin-6 (IL-6) antagonist as an active ingredient.
11 US2006292149A1
Variable antibodies
Publication/Patent Number: US2006292149A1 Publication Date: 2006-12-28 Application Number: 10/566,851 Filing Date: 2004-08-16 Inventor: Saint-remy, Jean-marie   Jacquemin, Marc   Assignee: D. COLLEN RESEARCH FOUNDATION VZW   IPC: A61K39/395 Abstract: The present invention discloses inhibitory antibodies against Factor VIII with modified glycosylation, either by enzymatic deglycosylation or by site directed mutagenesis. Said antibodies with modified glycosylation have equal affinity for FVIII but show different inhibiting properties. The use of one or a mixture of said antibodies allow modulation of the inhibition of factor VII to levels between 40 and 95%. The present invention further disclosed pharmaceutical compositions comprising inhibitory antibodies against Factor VIII with modified glycosylation, combinations of these antibodies and methods for treating haemostasis disorders using said antibodies and antibody mixtures. The present invention discloses inhibitory antibodies against Factor VIII with modified glycosylation, either by enzymatic deglycosylation or by site directed mutagenesis. Said antibodies with modified glycosylation have equal affinity for FVIII but show different inhibiting ...More ...Less
12 US2006292150A1
Methods of using wisp antagonists
Publication/Patent Number: US2006292150A1 Publication Date: 2006-12-28 Application Number: 10/570,826 Filing Date: 2004-09-09 Inventor: Desnoyers, Luc   Assignee: Desnoyers, Luc   IPC: A61K39/395 Abstract: Methods and compositions for use in blocking or inhibiting the activity(s) of WISP-1 polypeptide on chondrocytes are provided. WISP-1 antagonists include anti-WISP-1 antibodies, WISP-1 immunoadhesins and WISP-1 variants (and fusion proteins thereof) which inhibit or neutralize the effects of WISP-1 on mammalian chondrocytes. Methods and compositions for use in blocking or inhibiting the activity(s) of WISP-1 polypeptide on chondrocytes are provided. WISP-1 antagonists include anti-WISP-1 antibodies, WISP-1 immunoadhesins and WISP-1 variants (and fusion proteins thereof) which inhibit or neutralize ...More ...Less
13 US2006292169A1
Fusion proteins of mycobacterium tuberculosis antigens and their uses
Publication/Patent Number: US2006292169A1 Publication Date: 2006-12-28 Application Number: 11/511,587 Filing Date: 2006-08-28 Inventor: Reed, Steven   Skeiky, Yasir   Dillon, Davin   Alderson, Mark   Campos-neto, Antonio   Assignee: Corixa Corporation   IPC: A61K48/00 Abstract: The present invention relates to fusion proteins containing at least two Mycobacterium tuberculosis antigens. In particular, it relates to bi-fusion proteins which contain two individual M. tuberculosis antigens, tri-fusion proteins which contain three M. tuberculosis antigens, tetra-fusion proteins which contain four M. tuberculosis antigens, and penta-fusion proteins which contain five M. tuberculosis antigens, and methods for their use in the diagnosis, treatment and prevention of tuberculosis infection. The present invention relates to fusion proteins containing at least two Mycobacterium tuberculosis antigens. In particular, it relates to bi-fusion proteins which contain two individual M. tuberculosis antigens, tri-fusion proteins which contain three M. tuberculosis antigens ...More ...Less